FDA Panel, Reshaped by Corporate Interests, Votes to Lift Peptide Restrictions Despite Safety Risks
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
A committee organized by the FDA, now stacked with industry-aligned members, voted to recommend removing manufacturing limits on four peptides, disregarding the lack of human safety data and public health concerns.
On Thursday, a Food and Drug Administration advisory panel, whose composition was recently altered to include members with direct commercial interests, voted to recommend lifting manufacturing restrictions on four peptide substances intended for human use. The sharply divided panel moved forward with this recommendation, even as votes on three more peptides were postponed to the following day. This decision was made in blatant disregard for the absence of human safety and efficacy data for these compounds, putting public health at risk for the sake of private profit.
Earlier this year, Health and Human Services Secretary Robert F. Kennedy Jr. intervened to change the makeup of the panel, appointing new members who are deeply tied to the peptide manufacturing industry. Reports indicate that the original, presumably more impartial, members voted against the recommendation, but the industry-connected appointees tipped the scales in favor of deregulation.
Kennedy, echoing the interests of compounding pharmacies and industry lobbyists, has pushed for overturning a ban that protected the public from untested peptides. He claims that 'independent experts' will evaluate each substance based on scientific evidence, yet no such evidence was presented at the meeting—raising serious doubts about the integrity of the process.
While the panel’s recommendation is non-binding, the FDA still has the power to reject it. An FDA official reminded the committee that the agency has never approved a product lacking human testing, a standard now under threat by corporate influence. This outcome exposes the vulnerability of the drug review process to industry capture, especially for peptide drugs that have not undergone comprehensive clinical testing.